HIP1-ALK, a novel ALK fusion variant that responds to crizotinib

Journal of Thoracic Oncology

Volumn 9, Issue 3, 2014, Pages 285-294

  Fang, Douglas D ^a   Zhang, Bin ^a   Gu, Qingyang ^a   Lira, Maruja ^b   Xu, Qiang ^a   Sun, Hongye ^a   Qian, Maoxiang ^a   Sheng, Weiqi ^c   Ozeck, Mark ^b   Wang, Zhenxiong ^b   Zhang, Cathy ^b   Chen, Xinsheng ^a   Chen, Kevin X ^a   Li, Jian ^a   Chen, Shu Hui ^a   Christensen, James ^b   Mao, Mao ^b   Chan, Chi Chung ^a  

^a WUXI APPTEC   (China)

^b PFIZER INC   (United States)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

anaplastic lymphoma kinase; Crizotinib (PF 02341066); Echinoderm microtubule associated proteinlike 4; EML4 ALK; HIP1 ALK; Huntingtin interacting protein 1; Non small cell lung cancer; Patient derived xenograft (PDX) tumor model

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CISPLATIN; CRIZOTINIB; CYTOKERATIN 5; CYTOKERATIN 6; HUNTINGTIN INTERACTING PROTEIN 1; MICROTUBULE ASSOCIATED PROTEIN 4; PROTEIN; PROTEIN P63; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMOSOME 2; CHROMOSOME 7; CONTROLLED STUDY; ECHINODERM; EXON; FEMALE; GENE EXPRESSION; GENE FUSION; GENE REARRANGEMENT; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; DNA-BINDING PROTEINS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84894563860     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000087     Document Type: Article

References (41)

1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
2. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
3. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-566.
4. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007;6:3314-3322.
5. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
6. Mano H. Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci 2008;99:2349-2355.
7. Horn L, Pao W. EML4-ALK: Honing in on a new target in non-small-cell lung cancer. J Clin Oncol 2009;27:4232-4235.
8. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994;263:1281-1284.
9. Shiota M, Fujimoto J, Semba T, et al. Hyperphosphorylation of a novel 80 kDa protein-Tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 1994;9:1567-1574.
10. Hernandez L, Pinyol M, Hernandez S, et al. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood 1999;94:3265-3268.
11. Touriol C, Greenland C, Lamant L, et al. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 2000;95:3204-3207.
12. Ma Z, Cools J, Marynen P, et al. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood 2000;95:2144-2149.
13. Trinei M, Lanfrancone L, Campo E, et al. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALKpositive anaplastic large cell lymphoma. Cancer Res 2000;60:793-798.
14. Cools J, Wlodarska I, Somers R, et al. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Gen Chrom Cancer 2002;34:354-362.
15. Tort F, Campo E, Pohlman B, et al. Heterogeneity of genomic breakpoints in MSN-ALK translocations in anaplastic large cell lymphoma. Hum Pathol 2004;35:1038-1041.
16. Kinoshita Y, Tajiri T, Ieiri S, et al. A case of an inflammatory myofibroblastic tumor in the lung which expressed TPM3-ALK gene fusion. Pediatr Surg Int 2007;23:595-599.
17. Armstrong F, Lamant L, Hieblot C, et al. TPM3-ALK expression induces changes in cytoskeleton organisation and confers higher metastatic capacities than other ALK fusion proteins. Eur J Cancer 2007;43:640-646.
18. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009;15:3143-3149.
19. Togashi Y, Soda M, Sakata S, et al. KLC1-ALK: A novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One 2012;7:e31323.
20. Jung Y, Kim P, Keum J, et al. Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing. Genes Chromosomes Cancer 2012;51:590-597.
21. Ou SH, Bartlett CH, Mino-Kenudson M, et al. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: A success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 2012;17:1351-1375.
22. Lira ME, Kim TM, Huang D, et al. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer. J Mol Diagn 2013;15:51-61.
23. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-Type EGFR and KRAS. Cancer 2009;115:1723-1733.
24. Conway T, Wazny J, Bromage A, et al. Xenome-A tool for classifying reads from xenograft samples. Bioinformatics (Oxford, England) 2012;28:i172-178.
25. Kim D, Pertea G, Trapnell C, et al. TopHat2: Accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Gen Biol 2013;14:R36.
26. Trapnell C, Williams BA, Pertea G, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Natur Biotechnol 2010;28:511-515.
27. Kim D, Salzberg SL. TopHat-Fusion: An algorithm for discovery of novel fusion transcripts. Gen Biol 2011;12:R72.
28. Choi YL, Takeuchi K, Soda M, et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 2008;68:4971-4976.
29. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-1203.
30. Waelter S, Scherzinger E, Hasenbank R, et al. The huntingtin interacting protein HIP1 is a clathrin and alpha-Adaptin-binding protein involved in receptor-mediated endocytosis. Hum Mol Genet 2001;10:1807-1817.
31. Wilbur JD, Chen CY, Manalo V, et al. Actin binding by Hip1 (huntingtininteracting protein 1) and Hip1R (Hip1-related protein) is regulated by clathrin light chain. J Biol Chem 2008;283:32870-32879.
32. Bradley SV, Holland EC, Liu GY, et al. Huntingtin interacting protein 1 is a novel brain tumor marker that associates with epidermal growth factor receptor. Cancer Res 2007;67:3609-3615.
33. Gottfried I, Ehrlich M, Ashery U. The Sla2p/HIP1/HIP1R family: Similar structure, similar function in endocytosis?. Biochem Soc Trans 2010;38:187-191.
34. Ross TS, Bernard OA, Berger R, et al. Fusion of huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood 1998;91:4419-4426.
35. Ross TS, Gilliland DG. Transforming properties of the huntingtin interacting protein 1/ platelet-derived growth factor beta receptor fusion protein. J Biol Chem 1999;274:22328-22336.
36. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-4253.
37. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008;14:4275-4283.
38. Takeuchi K, Choi YL, Soda M, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008;14:6618-6624.
39. Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 2010;17:889-897.
40. Yoshida A, Tsuta K, Nakamura H, et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 2011;35:1226-1234.
41. Wong DW, Leung EL, Wong SK, et al. A novel KIF5B-ALK variant in nonsmall cell lung cancer. Cancer 2011;117:2709-2718.